However, this reduction did not reach statistical significance, most likely due to smaller population size. 9 These findings highlight the need for further large-scale trials to more definitively assess the therapeutic potential of asundexian in this patient population. 9 Building upon previous research, the phase 3 OCEANIC-AF trial, evaluated asundexian (10, 25, 50, and 100 mg once daily doses) versus apixaban for stroke prevention in high-risk patients with atrial fibrillation.
1
—
—